NASDAQ:CRBPCorbus Pharmaceuticals Stock Price, Forecast & News

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRBP stock has increased by 86.4% and is now trading at $7.68. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corbus Pharmaceuticals.

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Corbus Pharmaceuticals.

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) posted its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.03. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $1.64 million. Corbus Pharmaceuticals had a negative return on equity of 282.91% and a negative net margin of 207.87%. View Corbus Pharmaceuticals' earnings history.

8 analysts have issued 1-year price targets for Corbus Pharmaceuticals' shares. Their forecasts range from $22.00 to $112.00. On average, they expect Corbus Pharmaceuticals' share price to reach $39.13 in the next twelve months. This suggests a possible upside of 409.4% from the stock's current price. View analysts' price targets for Corbus Pharmaceuticals.

News coverage about CRBP stock has trended somewhat negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Corbus Pharmaceuticals.

Some companies that are related to Corbus Pharmaceuticals include IGM Biosciences (IGMS), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Xencor (XNCR), Dicerna Pharmaceuticals (DRNA), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Madrigal Pharmaceuticals (MDGL), I-Mab (IMAB), Intra-Cellular Therapies (ITCI) and Y-mAbs Therapeutics (YMAB). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Western Digital (WDC), Cronos Group (CRON) and Zynerba Pharmaceuticals (ZYNE).

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Aries Wealth Management (0.02%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View institutional ownership trends for Corbus Pharmaceuticals.

CRBP stock was sold by a variety of institutional investors in the last quarter, including Aries Wealth Management. View insider buying and selling activity for Corbus Pharmaceuticals.

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRBP stock can currently be purchased for approximately $7.68.

Corbus Pharmaceuticals has a market capitalization of $556.72 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 141 workers across the globe.

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]